JP4896333B2 - 薬理活性抗ウイルスペプチドおよびそれらの使用法 - Google Patents

薬理活性抗ウイルスペプチドおよびそれらの使用法 Download PDF

Info

Publication number
JP4896333B2
JP4896333B2 JP2001557903A JP2001557903A JP4896333B2 JP 4896333 B2 JP4896333 B2 JP 4896333B2 JP 2001557903 A JP2001557903 A JP 2001557903A JP 2001557903 A JP2001557903 A JP 2001557903A JP 4896333 B2 JP4896333 B2 JP 4896333B2
Authority
JP
Japan
Prior art keywords
peptide
antiviral
virus
peptides
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2001557903A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003522185A (ja
JP2003522185A5 (enExample
Inventor
ブラント，カーテイス
ブルトマン，ヘルマン
Original Assignee
ウイスコンシン アラムニ リサーチ ファンデーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ウイスコンシン アラムニ リサーチ ファンデーション filed Critical ウイスコンシン アラムニ リサーチ ファンデーション
Publication of JP2003522185A publication Critical patent/JP2003522185A/ja
Publication of JP2003522185A5 publication Critical patent/JP2003522185A5/ja
Application granted granted Critical
Publication of JP4896333B2 publication Critical patent/JP4896333B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2001557903A 2000-02-07 2001-02-06 薬理活性抗ウイルスペプチドおよびそれらの使用法 Expired - Fee Related JP4896333B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US18082300P 2000-02-07 2000-02-07
US60/180,823 2000-02-07
US18405700P 2000-02-22 2000-02-22
US60/184,057 2000-02-22
PCT/US2001/003813 WO2001057072A2 (en) 2000-02-07 2001-02-06 Pharmacologically active antiviral peptides and methods of their use

Publications (3)

Publication Number Publication Date
JP2003522185A JP2003522185A (ja) 2003-07-22
JP2003522185A5 JP2003522185A5 (enExample) 2011-04-21
JP4896333B2 true JP4896333B2 (ja) 2012-03-14

Family

ID=26876670

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001557903A Expired - Fee Related JP4896333B2 (ja) 2000-02-07 2001-02-06 薬理活性抗ウイルスペプチドおよびそれらの使用法

Country Status (9)

Country Link
US (3) US7371809B2 (enExample)
EP (1) EP1272510B1 (enExample)
JP (1) JP4896333B2 (enExample)
AT (1) ATE374208T1 (enExample)
AU (1) AU784264B2 (enExample)
CA (1) CA2399676C (enExample)
DE (1) DE60130641T2 (enExample)
ES (1) ES2293977T3 (enExample)
WO (1) WO2001057072A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2293977T3 (es) 2000-02-07 2008-04-01 Wisconsin Alumni Research Foundation Peptidos antivirales farmacologicamente activos y metodo para su uso.
AU2003210659A1 (en) * 2002-01-24 2003-09-02 Sangstat Medical Corporation Combination therapy for treatment of hiv infection
US7432045B2 (en) 2003-12-01 2008-10-07 Wisconsin Alumni Research Foundation Method of inhibiting influenza infection with antiviral peptides
JP4831410B2 (ja) 2006-02-28 2011-12-07 東亞合成株式会社 抗ウイルス性ペプチドおよび抗ウイルス剤
WO2009152518A1 (en) * 2008-06-13 2009-12-17 Wisconsin Alumni Research Foundation Novel peptide adjuvant for influenza vaccination
JP2011524373A (ja) 2008-06-13 2011-09-01 ウィスコンシン・アルムナイ・リサーチ・ファウンデーション インフルエンザウイルスに対する新規抗ウイルスペプチド
JP5996190B2 (ja) * 2008-09-19 2016-09-21 ヘンリー フォード ヘルス システムＨｅｎｒｙ Ｆｏｒｄ Ｈｅａｌｔｈ Ｓｙｓｔｅｍ カルパイン阻害のための方法、系および組成物
GB201012651D0 (en) * 2010-07-28 2010-09-15 Univ Edinburgh Peptides
JP6022470B2 (ja) 2010-11-24 2016-11-09 タカラ バイオ ユーエスエー， インコーポレイテッド 分散型タンパク質形質導入ドメインを含む誘導性発現系転写モジュレータおよびその使用方法
US20120190107A1 (en) * 2011-01-26 2012-07-26 Dwayne Bisgrove Enhanced protein transduction
ES2444299B1 (es) 2012-08-23 2014-12-12 Nutrición Técnica Deportiva, S.L. Uso de un hidrolizado de caseina como agente antiherpético
JP7233737B2 (ja) * 2017-05-26 2023-03-07 ビラマティクス スンディリアン ブルハド ペプチドおよび抗ウイルス剤としてのその使用
IL311034A (en) * 2021-08-23 2024-04-01 Amytrx Therapeutics Inc Molecules penetrate leukocytes specifically

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4795740A (en) * 1986-05-20 1989-01-03 Cohen Eric A Antiviral peptides and means for treating herpes infections
US4814432A (en) 1987-05-22 1989-03-21 Merck & Co., Inc. Inhibitor of ribonucleotide reductase
US5260420A (en) 1987-07-30 1993-11-09 Centre Regional De Transfusion Sanguine De Lille Concentrate of thrombin coagulable proteins, the method of obtaining same and therapeutical use thereof
US5104854A (en) 1989-02-01 1992-04-14 Washington University Antiviral peptides
CA1340682C (en) 1989-07-07 1999-07-27 Pierre Lavallee Antiviral peptides having a 2-oxoalkyl amino acid side chain
IT1231342B (it) 1989-08-28 1991-11-28 Prodotti Antibiotici Spa Derivati peptidici farmacologicamente attivi e preparazioni farmaceutiche che li contengono
JPH0421635A (ja) * 1990-05-16 1992-01-24 Suntory Ltd アセトアルデヒドの毒性抑制剤およびアセトアルデヒドの毒性抑制に有効な飲食物
CA2033447C (en) 1990-12-31 1999-08-31 Robert Deziel Synergistic combination for treating herpes infections
JPH05310784A (ja) 1991-09-04 1993-11-22 Merck & Co Inc ヒト乳頭腫ウイルスタンパク質と網膜芽細胞腫遺伝子タンパク質との結合のペプチド阻害剤
ATE273035T1 (de) 1993-11-03 2004-08-15 Clarion Pharmaceuticals Inc Hämostatisches pflaster
US5441936A (en) 1993-12-07 1995-08-15 Houghten Pharmaceuticals, Inc. Antiviral peptides
US5807746A (en) 1994-06-13 1998-09-15 Vanderbilt University Method for importing biologically active molecules into cells
FR2739621B1 (fr) 1995-10-05 1997-12-05 Centre Nat Rech Scient Peptides utilisables comme vecteurs pour l'adressage intracellulaire de molecules actives
AU3982497A (en) 1996-07-30 1998-02-20 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Double-stranded rna dependent protein kinase derived peptides to promote proliferation of cells and tissues in controlled manner
US5877282A (en) * 1996-09-20 1999-03-02 Bristol-Myers Squibb Company Peptide inhibitors of nuclear protein translocation having nuclear localization sequences and methods of use thereof
WO1998047913A2 (en) * 1997-04-18 1998-10-29 The University Of Medicine And Dentistry Of New Jersey Inhibition of hiv-1 replication by a tat rna-binding domain peptide analog
AU741546B2 (en) 1997-07-24 2001-12-06 Perseptive Biosystems, Inc. Conjugates of transporter peptides and nucleic acid analogs, and their use
FR2766826B1 (fr) * 1997-08-04 2001-05-18 Pasteur Institut Vecteurs derives d'anticorps pour le transfert de substances dans les cellules
EP1086126A1 (en) 1998-06-10 2001-03-28 The Queen's University of Belfast Cell-permeable peptide
ES2293977T3 (es) 2000-02-07 2008-04-01 Wisconsin Alumni Research Foundation Peptidos antivirales farmacologicamente activos y metodo para su uso.
US7432045B2 (en) 2003-12-01 2008-10-07 Wisconsin Alumni Research Foundation Method of inhibiting influenza infection with antiviral peptides

Also Published As

Publication number Publication date
EP1272510B1 (en) 2007-09-26
ES2293977T3 (es) 2008-04-01
CA2399676C (en) 2010-04-06
US8748565B2 (en) 2014-06-10
AU784264B2 (en) 2006-03-02
US20090253624A1 (en) 2009-10-08
CA2399676A1 (en) 2001-08-09
DE60130641T2 (de) 2008-06-26
JP2003522185A (ja) 2003-07-22
DE60130641D1 (de) 2007-11-08
WO2001057072A3 (en) 2002-10-31
WO2001057072A2 (en) 2001-08-09
US8748566B2 (en) 2014-06-10
AU3670001A (en) 2001-08-14
EP1272510A2 (en) 2003-01-08
US20120157376A1 (en) 2012-06-21
ATE374208T1 (de) 2007-10-15
US20050130884A1 (en) 2005-06-16
US7371809B2 (en) 2008-05-13

Similar Documents

Publication Publication Date Title
US8748566B2 (en) Pharmacologically active antiviral peptides and methods of use
USRE47838E1 (en) Inhibitory peptides of viral infection
US5441936A (en) Antiviral peptides
JP2724711B2 (ja) 医薬品生成物
US4800081A (en) Methods and compositions for treating viral infections
Akkarawongsa et al. Corneal toxicity of cell-penetrating peptides that inhibit herpes simplex virus entry
US4663317A (en) Methods and compositions for treating viral infections
US4849412A (en) Methods and compositions for treating viral infections
US7432045B2 (en) Method of inhibiting influenza infection with antiviral peptides
Hayashi et al. Yucca leaf protein (YLP) stops the protein synthesis in HSV-infected cells and inhibits virus replication
JP2938916B2 (ja) ヘルペスウィルスの増殖阻害および潜伏感染後の再発阻止剤
AU2006202024B2 (en) Pharmacologically active antiviral peptides and methods of their use
JP2877908B2 (ja) 抗ヘルペスペンタペプチド類
EP1862471A2 (en) Pharmacologically active antiviral peptides and methods of their use
SK29795A3 (en) Inhibition of retrovirus infection
CN100390183C (zh) 稀土杂多化合物抗病毒药物
JP2001072597A (ja) 抗ヘルペスウイルス剤
JP2020059662A (ja) 抗ウイルス性ペプチドおよびその利用
Upadhyay et al. The effect of HSV multiplication rate on antiviral drug efficacy in vitro
Galasso Promises to keep: clinical use of antiviral drugs
Varadinova et al. In vitro Antiherpes Activity of Oxadin®
IL90783A (en) Method for preventing the transmission of non-human living biological material to the VIH virus by using the antibiotic substance UB-8063
CN107881170A (zh) 核酸分子ctl4hsh11、其制备方法及应用
CN108070591A (zh) 核酸分子ctl4hsh4、其制备方法及应用
CN107868783A (zh) 核酸分子ctl4hsh2、其制备方法及应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071119

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100831

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101124

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110228

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20110228

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110524

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110922

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20111125

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20111213

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20111221

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150106

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees